PYC Therapeutics Advances RNA Pipeline with $600m Capital Boost and Clinical Milestones

Capital Raise Strengthens Financial Position

PYC Therapeutics (ASX:PYC) kicked off 2026 by bolstering its war chest with a $600 million capital raise, attracting a syndicate of leading global life sciences investors. This infusion, combined with a subsequent $23 million R&D rebate, lifted cash reserves to $667 million by quarter-end, underpinning a runway of approximately 41 quarters at current operating levels.

The capital raise follows a series of funding rounds earlier in the year, including a $47 million retail entitlement offer in March, reflecting sustained investor appetite for PYC’s RNA therapeutic pipeline. The fresh capital is earmarked to accelerate clinical development across four precision medicine programs targeting genetic diseases lacking effective treatments.

Polycystic Kidney Disease Program Advances Dose Escalation

PYC’s lead candidate for Autosomal Dominant Polycystic Kidney Disease (PKD) marked a significant clinical milestone by initiating dosing in the highest cohort of its Single Ascending Dose (SAD) study. This progress came after the Safety Review Committee cleared continuation following positive safety data from earlier cohorts.

The company is now preparing to launch the Multiple Ascending Dose (MAD) study in Q2 2026, a critical step aimed at establishing clinical proof of concept for this drug candidate in a disease affecting over 10 million people worldwide, most of whom have no treatment options. The MAD study’s outcomes will inform the design of a registrational Phase 2/3 trial, contingent on regulatory approval.

Retinal Disease Programs Show Regulatory and Clinical Progress

In the Retinitis Pigmentosa type 11 (RP11) program, PYC secured FDA alignment on the registrational study design for its VP-001 candidate, a pivotal step toward a New Drug Application. This follows a Type D meeting with the agency, clarifying key trial elements to support regulatory approval.

Looking ahead, PYC expects to update on Phase 2 study data in Q4 2026, including vision improvements in patients exposed to VP-001 for over 12 months. Notably, the RP11 candidate recently received Orphan Drug Designation from the European Medicines Agency, enhancing its regulatory and commercial prospects in Europe EMA Orphan Drug Designation.

Meanwhile, the Autosomal Dominant Optic Atrophy (ADOA) program advanced with enrolment in repeat dose cohorts and presentation of safety and efficacy data at the North American Neuro-Ophthalmology Society conference. The transition to multiple dosing for the 60 microgram cohort is underway, with further clinical readouts expected through 2026 and 2027, supporting global registrational plans ADOA Multiple Dose Study.

Phelan-McDermid Syndrome Program Progresses Preclinical Milestones

PYC’s fourth drug candidate targets Phelan-McDermid Syndrome (PMS), a severe neurodevelopmental disorder. During Q1, dose-range finding studies in rodents and non-human primates advanced ahead of planned Good Laboratory Practice toxicology studies slated for Q2 2026.

The company aims to submit an Investigational New Drug application to the FDA in the first half of 2027, setting the stage for first-in-human trials. This program complements PYC’s focus on monogenic diseases with high clinical development success rates.

Operational and Financial Discipline Maintained

Operating expenses during the quarter primarily reflected ongoing clinical trials, regulatory submissions, and discovery program progression, with research and development payments totaling $16.7 million. Administrative and staff costs remained controlled, and related party payments of $244,000 were disclosed, covering director remuneration.

PYC’s strong cash position and recent capital injections provide a solid foundation to navigate the inherent risks and uncertainties of clinical development, including regulatory approvals and trial outcomes. Investors will be watching closely as the company advances multiple clinical milestones and regulatory engagements across its pipeline.